Brace for an end-of-year boost to drug approvals

An apparent slowdown at the FDA has biopharma fretting. With the sector struggling to beat off a bear market, the last thing downtrodden developers need are regulatory worries.

Extreme concern is probably a bit premature, at least according to Evaluate Vantage’s look at what remains on the cards for 2022. Several important verdicts are due in the final months of the year, with November looking particularly busy.